Next Article in Journal
Disulfides from the Brown Alga Dictyopteris membranacea Suppress M1 Macrophage Activation by Inducing AKT and Suppressing MAPK/ERK Signaling Pathways
Previous Article in Journal
Pseudoceratonic Acid and Moloka’iamine Derivatives from the Red Sea Verongiid Sponge Pseudoceratina arabica
 
 
Search for Articles:
Title / Keyword
Author / Affiliation / Email
Journal
Article Type
 
 
Advanced Search
 
Section
Special Issue
Volume
Issue
Number
Page
 
Journals
Marine Drugs
Volume 18
Issue 11
10.3390/md18110526
marinedrugs-logo
Submit to this Journal Review for this Journal Propose a Special Issue
► Article Menu

Article Menu

share Share announcement Help format_quote Cite question_answer Discuss in SciProfiles thumb_up
...
Endorse textsms
...
Comment
first_page
settings
Order Article Reprints
Font Type:
Arial Georgia Verdana
Font Size:
Aa Aa Aa
Line Spacing:
Column Width:
Background:
Article

Synthesis and Biological Evaluation of Analogues of Butyrolactone I as PTP1B Inhibitors

by
Bihong Hong
1,2,*,†,
Jianlin He
1,2,†,
Chaochun Fan
2,3,
Chao Tang
1,2,
Qingqing Le
1,2,
Kaikai Bai
1,2,
Siwen Niu
1,2 and
Meitian Xiao
3,*
1
Third Institute of Oceanography, Ministry of Natural Resources, Xiamen 361005, China
2
Technical Innovation Center for Exploitation of Marine Biological Resources, Ministry of Natural Resources, Xiamen 361005, China
3
College of Chemical Engineering, Huaqiao University, Xiamen 361021, China
*
Authors to whom correspondence should be addressed.
†
Bihong Hong and Jianlin He contributed equally to this work.
Mar. Drugs 2020, 18(11), 526; https://doi.org/10.3390/md18110526
Submission received: 26 September 2020 / Revised: 16 October 2020 / Accepted: 21 October 2020 / Published: 23 October 2020
Browse Figures
Versions Notes

Abstract

:
In recent years, a large number of pharmacologically active compounds containing a butenolide functional group have been isolated from secondary metabolites of marine microorganisms. Butyrolactone I was found to be produced by Aspergillus terreus isolated from several marine-derived samples. The hypoglycemic activity of butyrolactone I has aroused our great interest. In this study, we synthesized six racemic butenolide derivatives (namely BL-1–BL-6) by modifying the C-4 side chain of butyrolactone I. Among them, BL-3 and BL-5 improved the insulin resistance of HepG2 cells and did not affect the proliferation of RIN-m5f cell line, which indicated the efficacy and safety of BL-3 and BL-5. Furthermore, BL-3, BL-4, BL-5, and BL-6 displayed a significant protein tyrosine phosphatase 1B (PTP1B) inhibitory effect, while the enantiomers of BL-3 displayed different 50% percentage inhibition concentration (IC50) values against PTP1B. The results of molecular docking simulation of the BLs and PTP1B explained the differences of biological consequences observed between the enantiomers of BL-3, which supported BLs as PTP1B inhibitors, and also indicated that the chirality of C-4 might influence the inhibitory effect of the BLs. Our findings provide a novel strategy for the development of butyrolactone derivatives as potential PTP1B inhibitors for the treatment of type 2 diabetes mellitus.

1. Introduction

Type 2 diabetes mellitus (T2DM), characterized by high blood sugar in the context of insulin resistance (IR) and a relative lack of insulin [1], is a long-term, non-communicable, multisystem disease that has reached epidemic proportions [2]. Chronic exposure to hyperglycemia affects the microvasculature, eventually leading to diabetic blindness, renal failure, and several neurological disorders with a high impact on the quality of life and overall life expectancy [3]. T2DM is associated with a significant shorter life expectancy [4,5]. Furthermore, accumulating data suggest that younger adults (aged <40 years) with T2DM with a more rapid deterioration of β-cell function than in later-onset T2DM, has increased in both developing and developed countries [6]. Therefore, T2DM and its related complications represent an urgent public health problem.
The living environment is harsh to marine invertebrates such as sea hares, sponges, etc. A large number of epiphytes help them to survive by producing secondary metabolites that may be involved in the chemical defense of the host [7,8]. The metabolites display antibacterial, antiviral, antitumor and other activities [9,10,11]. Butenolide, a collective name for α,β-unsaturated lactones with four carbon heterocyclic rings produced by a variety of marine organisms, is drawing increasing attention in drug discovery [12,13,14,15,16]. Butenolide derivatives display an impressive range of pharmacological properties, including anti-inflammatory [17,18], antibacterial [19], antiviral [20], and antitumor activities [21,22], while aromatic butenolides were found to have α- and β-glucosidase inhibitory activities [23,24]. Protein tyrosine phosphatase 1B (PTP1B) is one of the key members of the PTP family and an important hypoglycemic target which plays a very important role in catalyzing protein tyrosine dephosphorylation and regulating multiple signal transduction pathways [25]. However, the effects of the butenolides on PTP1B were less frequently reported.
Butyrolactone I is a butenolide that can be produced by several marine-derived Aspergillus terreus [26,27,28]. Butyrolactone I has various biological activities. It regulates cell cycle by selectively inhibiting cyclin-dependent kinases (CDKs), including CDK1, CDK2, and CDK5 [29,30]. It is also an efficient inhibitor of the α-glucosidase with a 50% percentage inhibition concentration (IC50) of 52.17 μM [31], and has antioxidant activities with an IC50 of 51.39 μM [32]. Recently, it was found to improve T2DM with potent TNF-α lowering properties through modulating gut microbiota in db/db mice [33]. The adiponectin production-enhancing activity of butyrolactone I was explained by its dual modulator activities as both a CDK5 inhibitor and a peroxisome proliferator-activated receptor γ partial agonist [34]. Additionally, both natural and synthetic analogues of butyrolactone I exhibited interesting biological activities, including anti-microbial and antitumor effects [35,36,37].
In this paper, several 2(5H)-furanone compounds (namely BL-1–BL-6) were synthesized by aldol condensation and lactonization based on the modification of the C-4 side chain of butyrolactone I (Figure 1). The hypoglycemic effect of the synthesized compounds was evaluated by PTP1B inhibitory assay, and the effects on glucose uptake was investigated in IR HepG2 cells. Molecular simulation approaches were conducted to explore the interactions between PTP1B and the synthesized compounds.

2. Results and Discussion

2.1. Chemistry

The strategy was to synthesize two intermediates separately and combine them into the lactone ring of the butenolide. Firstly, the active methylene intermediate was synthesized according to Scheme 1. 4-Hydroxybenzaldehyde (1a) was condensed with hydantoin (Knoevenagel condensation), and then 4-hydroxyphenylpyruvate (S1) was obtained through hydrolysis. Methyl p-hydroxyphenylpyruvate (S2) was obtained by quantified esterification of S1 in methanol under the catalysis of trimethyl chlorosilane (TMCS).
Secondly, three types of carbonyl compounds were synthesized. Scheme 2 shows the synthesis scheme for the first type. p-Hydroxybenzaldehyde (1a) generated phenol oxide anions under potassium hydroxide (KOH), which reacted with chloroisoprene to form intermediate 1b via Friedel–Crafts alkylation [38,39]. Under 2,3-dichloro-5,6-dicyano-1,4-benzoquinone (DDQ), 1b was refluxed in toluene to form the pyran ring to obtain 1c [40]. Moreover, 1b was protected by tetrahydropyran (THP) and benzyl to obtain 1d and 1e, respectively [41,42].
The second type was synthesized according to Scheme 3. In the presence of sodium hydroxide (NaOH), 4-hydroxymandelic acid (2b) was obtained via alkylation of phenol (2a) and glyoxylic acid [43], then esterification with methyl iodide under the catalysis of sodium carbonate to yield 4-hydroxymandelic acid (2c) [44]. Compound 2c underwent 2,2,6,6-tetramethylpiperidine-1-oxyl (TEMPO)/Ca(ClO)₂ oxidation under benzyl protection to produce carbonyl compound 2d [45].
The third type was synthesized according to Scheme 4. Phenoxyethanol (3a) generated phenol oxide anions under KOH, which reacted with chloroisoprene to form intermediate 3b via Friedel-Crafts alkylation [38]. Under benzyl protection, 3a and 3b were oxidized under dimethyl sulfoxide (DMSO) and sulfur trioxide pyridine complex to obtain 3e and 3f via Parikh–Doering oxidation [46].
Finally, catalyzed by 1,8-diazabicyclo[5.4.0]undec-7-ene (DBU), 1c, 1d, 1e, 2d, 3e, and 3f underwent aldol condensation and lactonization with S2 respectively (Scheme 5) to obtain butenolides BL-1–BL-6 [47].
Under the catalysis of DBU, C-4 is racemic. We performed chiral resolution and biological activity assay of the preferred compounds (with better biological activities) to evaluate the influence of chirality. The enantiomers of BL-3 and BL-5 were well separated by semi-preparative liquid chromatography with chiral columns.

2.2. Biology

The hypoglycemic effect of the synthesized compounds was evaluated by glucose consumed in IR model of HepG2 cell line by high glucose and high insulin stimulation, and rosiglitazone (Ros) was employed as a positive control.
The results showed that BL-3 and BL-5 displayed significant hypoglycemic effect, and BL-5 at 20 μM had similar potency to Ros at 5 μM (Figure 2a). At the same time, the compounds tested displayed no significant cytotoxicity to HepG2 cells at the designated concentrations (Figure 2b), which is very important to evaluate the hypoglycemic effect since the influence of the cytotoxic effect on the cells has been excluded.
RIN-m5f cell line was used to evaluate the toxicity of the compounds to islet cells. As shown in Figure 3, BL-6 exhibited significant cytotoxicity to RIN-m5f cell line. Additionally, BL-6 did not improve the glucose uptake in IR HepG2 cell (Figure 2a), and therefore BL-6 was not ideal for T2DM treatment.
Chirality is caused by spatial specific orientation of an asymmetric atom. Although enantiomers have the same physicochemical properties in achiral environments, they may have different biological activities due to their different optical activities. The three-dimensional arrangement of chiral molecules also affects their interaction with enzymes or receptors. The comparison of the hypoglycemic activity of the chiral enantiomers of BL-3 (BL-3-1 and BL-3-2) and BL-5 (BL-5-1 and BL-5-2) is shown in Figure 4. The results indicated that the chiral stereo structure of C-4 has no significant influence on the glucose uptake of BL-5, but might have influence on that of BL-3 (Figure 4).
Based on the results of the IR model, PTP1B inhibitory assay was further established based on reported methods [48] to explain the effects of the synthesized BLs on the glucose uptake.
The IC50 values were shown in Figure 5. Sodium orthovanadate (Na3VO4) was used as the positive control. BL-3, BL-4, BL-5, and BL-6 showed strong PTP1B inhibitory activity. BL-3-2 had a significantly lower IC50 than BL-3-1, while there were no obvious differences between the IC50 values of the enantiomers of BL-5.
The differences of the amount of glucose consumed and the IC50 values against PTP1B were observed between BL-3-1 and BL-3-2, which implied that the three-dimensional arrangement of the C-4 might influence the interactions between PTP1B and the compounds. Therefore, to explore the underlying mechanism, the absolute configuration of C-4 of BL-3 and BL-5 were determined, and molecular docking simulation of the compounds and PTP1B were performed. As shown in Figure 6, BL-3-1 was determined as BL-3(R) and BL-5-1 was determined as BL-5(R).
The docking data showed that BL-3 and BL-5 could be embedded into the active site of PTP1B, and the lactone core and the 3-phenyl were essential for the docking (Figure 7 and Figure 8). Interestingly, BL-3(R) physically interacted with residues Ser216, Ile219, and Arg221, with a binding energy of –4.73 kcal/mol. While BL-3(S) illustrated more H-bond interactions than BL-3(R), and showed a –9.19 kcal/mol binding energy (Figure 7). The differences of the docking scores indicated that BL-3(S) might have a greater potency of inhibiting PTP1B than BL-3(R), which was supported by the data of PTP1B inhibitory assay shown in Figure 5C. Additionally, as shown in Figure 8, BL-5(R) and BL-5(S) showed close binding energies, indicating close potencies of the enantiomers of BL-5 against PTP1B, which was supported by the data shown in Figure 5E.
Taken together, these simulated molecular docking results were concordant with the results of PTP1B inhibitory assay in vitro (Figure 5), and partly explained the glucose consumed assay data using HepG2 cell line (Figure 4). Therefore, the binding could be responsible for the inhibition of BLs against PTP1B, contributing to the currently observed biological consequences. Our results suggest analogues of butyrolactone I as PTP1B inhibitors. However, the IC50 values against PTP1B of the BLs synthesized in this paper were at micromolar level. Therefore, the hypoglycemic effects observed should not attributed to PTP1B inhibition only.

3. Materials and Methods

3.1. Reagents

Silica gel 60 F254 plates for thin layer chromatography (TLC) and silica gel (300–400 mesh) for column chromatography were purchased from Jiangyou Silica Gel Development, Inc. (Yantai, China). Other reagents and solvents were purchased from Aladdin Reagent Co., Ltd. (Shanghai, China). All moisture- and air-sensitive reactions were carried out using dry solvents under a static atmosphere of nitrogen.

3.2. Synthesis Methods

3.2.1. Synthesis of (Z)-2-Hydroxy-3-(4-Hydroxyphenyl) Acrylic Acid (S1)

Briefly, 4-Hydroxybenzaldehyde (12.2 g, 0.1 mol, 1.0 eq), hydantoin (11.1 g, 0.11 mol, 1.1 eq) and 20 mL of dry piperidine were mixed and stirred at 130 °C for 50 min. After that, the reaction was cooled to 80 °C, water (400 mL) at 60 °C was added, and stirred for 5 min. Then, the mixture was filtered off. The filtrate was acidified with 20 mL of concentrated hydrochloric acid and stirred at room temperature for 1 h. The resulting precipitate was filtered and washed with ice water (3 × 20 mL). The obtained yellow precipitate was dissolved in 20% NaOH (450 mL), and heated to 145 °C, refluxed for 5 h, then cooled. About 150 mL of concentrated hydrochloric acid was added dropwise at room temperature to adjust the pH to about 2, the mixture was extracted using 150 mL of ether for 3 times, dried over with anhydrous sodium sulfate (Na2SO4) and concentrated to obtain a yellow solid, which was then recrystallized with 10% dilute hydrochloric acid to obtain about 9.7 g of a light yellow solid in 61% yield.

3.2.2. Synthesis of Methyl (2Z)-2-Hydroxy-3-(4-Hydroxyphenyl) Acrylate (S2)

Briefly, 4-Hydroxyphenylpyruvate (S1, 0.1 mol) and freshly distilled trimethylchlorosilane (0.2 mol) were dissolved in anhydrous methanol (100 mL). Then, the solution was stirred at 25 °C overnight. After the reaction was completed (monitored by TLC), the reactant was concentrated on a rotary evaporator to obtain the product S2, red solid, in 98% yield.

3.2.3. Synthesis of 4-((3-Methylbut-2-en-1-yl) Oxy) Benzaldehyde (1a) and 4-Hydroxy-3-(3-Methylbut-2-en-1-yl) Benzaldehyde (1b)

p-Hydroxybenzaldehyde (12.3 g, 0.1 mol), KOH (5.6 g, 0.1 mol), and pure water (120 mL) were mixed. Then, chloroisopentene (12.5 g, 0.12 mol) was added dropwise with stirring at room temperature. The reaction was monitored with TLC. After the reaction was completed, the pH was adjusted to 3 with 3 mol/L hydrochloric acid, and then the reaction mixture was extracted with ethyl acetate (EA, 3 × 100 mL). The organic phases were combined, washed with saturated sodium carbonate solution and saturated brine, dried over anhydrous Na2SO4, and concentrated under reduced pressure to obtain a yellow oil, which was then subjected to a silica gel column chromatography with petroleum ether (PE)-EA (8:1, v/v) as the mobile phase to obtain 4.12 g of 1a in 21.7% yield and 3.23 g of 1b in 17.3% yield.

3.2.4. Synthesis of 2,2-Dimethyl-2H-Chromene-6-Carbaldehyde (1c)

To 5 mL of toluene, 1b (0.39 g, 2 mmol) and DDQ (0.5 g, 2 mmol) was added, and stirred under reflux for 4 h. Then the mixture was filtered off, and the filtrate was concentrated under reduced pressure and purified on a silica gel column with mobile phase of PE-EA (5:1, v/v) to obtain 0.35 g of a colorless oil (1c) in 92.6% yield.

3.2.5. Synthesis of 3-(3-Methylbut-2-en-1-yl)-4-((Tetrahydro-2H-Pyran-2-yl) Oxy) Benzaldehyde (1d)

To 5mL of 3,4-dihydro-2H-pyran, 1b (0.39 g, 2 mmol) and pyridinium p-toluenesulfonate (0.05 g, 0.2 mmol) were added, and then stirred under reflux for 1 h. After the reaction was completed, the solvent was distilled off, and the residue was washed with water (2 × 30 mL) to obtain 0.47 g of colorless oil (1d) with a yield of 86.3%.

3.2.6. Synthesis of 4-(Benzyloxy)-3-(3-Methylbut-2-en-1-yl) Benzaldehyde (1e)

In a round bottom flask, 1b (0.39 g, 0.002 mol), K2CO3 (0.28 g, 0.0021 mol), benzyl bromide (0.38 g, 0.0022 mol), and 20 mL of acetonitrile were mixed, refluxed for 2 h, and filtered off. The filtrate was concentrated under reduced pressure. The residue was then purified on a silica gel column chromatography with PE-EA (10:1, v/v) as the mobile phase to obtain 0.51 g of a colorless oil (1e), with a yield of 91.2%.

3.2.7. Synthesis of 2-Hydroxy-2-(4-Hydroxyphenyl) Acetic Acid (2b)

Glyoxylic acid monohydrate (9.2 g, 0.1 mol) and NaOH (4 g, 0.1 mol) were added to 50 mL water to prepare the glyoxylic acid solution. Then, 2 g of NaOH was dissolved in 50 mL water to make a NaOH solution. NaOH (2 g, 0.05 mol), phenol (9.4 g, 0.1 mol), and 50 mL of pure water were added and heated to 50 °C, then the glyoxylic acid solution and the NaOH solution prepared were added dropwise at the same time over a 30 min period, and stirred for another 4 h. After that, the pH was adjusted to 2 with concentrated hydrochloric acid. The mixture was then extracted with EA (3 × 100 mL), dried and concentrated under reduced pressure to obtain a pale-yellow oil, which was recrystallization in PE to obtain 12.7 g of white solid (2b) in 76.2% yield.

3.2.8. Synthesis of Methyl 2-Hydroxy-2-(4-Hydroxyphenyl) Acetate (2c)

To 80 mL of anhydrous N, N-dimethylformamide (DMF), 2b (3.4 g, 0.02 mol), methyl iodide (2.9 g, 0.02 mol), and sodium carbonate (2.2 g, 0.021 mol) were added. The resulting mixture was heated to 40 °C, and stirred for about 2 h (monitored with TLC detection). After the reaction, 50 mL of pure water was added, and the pH was adjusted to about 5. The mixture was then extracted with EA (3 × 50 mL), dried, and concentrated under reduced pressure to obtain 2.9 g of white solid (2c) in 83% yield.

3.2.9. Synthesis of Methyl 2-(4-(Benzyloxy) Phenyl)-2-Oxoacetate (2d)

Briefly, 2c (1.8 g, 0.01 mol), anhydrous potassium carbonate (2.9 g, 0.011 mol), benzyl bromide (3.8 g, 0.012 mol), and 60 mL of acetonitrile were mixed. The reaction was refluxed at 75 °C, and the progress of the reaction was monitored by TLC. After 2c was depleted, the reaction mixture was cooled to room temperature, and the catalyst was removed by filtration. TEMPO (0.05 g) and calcium hypochlorite (1.4 g, 0.01 mol) were added to the reaction mixture at 0 °C, and stirred for another 2 h at room temperature, then filtered off, concentrated to obtain the yellow liquid. Silica gel column chromatography (mobile phase of PE-EA, 30:1, v/v) was employed to obtain pure white solid (2d) 1.5 g, in 56% yield.

3.2.10. Synthesis of 4-(2-Hydroxyethyl)-2-(3-Methylbut-2-en-1-yl) Phenol (3b)

Phenoxyethanol (3a) reacted with chloroisoprene to form 3b via Friedel–Crafts alkylation. The synthetic process was the same as that of 1b, described in Section 3.2.3.

3.2.11. Synthesis of 2-(4-(Benzyloxy)-3-(3-Methylbut-2-en-1-yl) Phenyl) Ethan-1-ol (3c) and 2-(4-(Benzyloxy) Phenyl) Ethan-1-ol (3d)

Briefly, 3a and 3b reacted with benzyl bromide to yield 3d and 3c, respectively. The synthetic process was the same as that of 1e, described in 3.2.6.

3.2.12. Synthesis of 2-(4-(Benzyloxy)-3-(3-Methylbut-2-en-1-yl) Phenyl) Acetaldehyde (3e) and 2-(4-(Benzyloxy) Phenyl) Acetaldehyde (3f)

Sulfur trioxide pyridine complex (3.2 g, 0.02 mol) and DMSO (8 mL) were stirred at room temperature for 15 min to prepare Parikh-Doering intermediate. 3c (1.5g, 0.0066 mol), 6 mL of triethylamine, 7 mL of DMSO, and 30 mL of dichloromethane were mixed and cool to 0 °C. The prepared intermediate was added dropwise to the reaction solution. After 1 h, the reaction mixture was quenched with 150 mL of ice water, extracted with dichloromethane, washed with saturated brine, dried over anhydrous Na2SO4, and concentrated under reduced pressure to obtain a colorless oil. Silica gel column chromatography (mobile phase of PE-EA, 8:1, v/v) was employed to obtain pure white solid (3e) 1.05 g, in 70.4% yield. Similarly, 3d underwent the same reaction process of Parikh-Doering oxidation to yield 3f.

3.2.13. Synthesis of the 4,5-Diaryl-3-Hydroxy-2(5H) Furanones BL-1–BL-6: General Procedure

At 0 °C, 2-oxo-3-phenylpropionic acid methyl ester (5.27 mmol) and the appropriate carbonyl compound (1.3 equivalents, 6.85 mmol) were added into dry DMF (24 mL). After cooling to 0 °C, DBU (0.80 mL, 5.35 mmol) was added dropwise, the reaction was stirred at 0 °C for 3–5 h, and then poured into hydrogen chloride (HCl, 1mol/L, 50 mL). The organic layer was separated, and the aqueous layer was extracted with EA. The organic layers were combined, dried over Na2SO4 and concentrated in vacuo, and then purified with column chromatography (mobile phase of EA-PE, 2:1, v/v) to obtain BL-1–BL-6. The purity of each compound was ≥98.0% by peak area normalization of high-performance liquid chromatography.

3.2.14. Chiral Resolution of BL-3 and BL-5

For BL-3, the chiral resolution was performed on a P230A/P semi-preparative liquid chromatography (Dalian Elite Analytical Instrument Co., Ltd., Dalian, China) with Chiral A4-5 (10 × 250 mm, 5 μm, Column Tek, State College, PA, USA) column to obtain BL-3-1 and BL-3-2. The mobile phase was methanol-water (90:10, v/v, 0.1% formic acid in water) with isocratic elution. The flow rate was 2.5 mL/min, and the detection wavelength was set at 304 nm.
For BL-5, the chiral resolution was performed on a P230A/P semi-preparative liquid chromatography with Chiral A1-5 (10 × 250 mm, 5 μm, Column Tek) column to obtain BL-5-1 and BL-5-2. The mobile phase was methanol-acetonitrile-water (30:30:40, v/v, 0.1% formic acid in water) with isocratic elution. The flow rate was 2.5 mL/min, and the detection wavelength was set at 303 nm.

3.2.15. Determination of Absolute Configuration of BL-3 and BL-5

The experimental circular dichroism (CD) spectra were recorded using a Chirascan CD Spectrophotometer (Applied Photophysics Ltd., Surrey, UK).
The conformational search was carried out via random searching in the Sybyl-X 2.0 (Tripos Associates, St Louis, MO, USA) using the MMFF94S force field with an energy cutoff of 3.0 kcal/mol. The conformers were re-optimized with the density functional theory calculations at the b3lyp/6-311+g(2d,p) level in gas phase by the GAUSSIAN 09 program [49]. The energies, oscillator strengths, and rotational strengths of the first 60 electronic excitations were calculated by time-dependent density-functional theory methodology at the b3lyp/6-311++g(2d,p) level in MeOH. The electronic circular dichroism (ECD) spectra were simulated by the overlapping Gaussian function (half the bandwidth at 1/e peak height, σ = 0.3) [50]. To get the final spectra, the simulated spectra of the conformers were averaged according to the Boltzmann distribution theory and their relative Gibbs free energy. The theoretical ECD spectrum of the corresponding enantiomer was obtained direct inversion of the ECD spectrum of the calculated model molecule, respectively.
The absolute configurations of BL-3 and BL-5 were determined by the comparison of their corresponding experimental and calculated CD spectra, respectively.

3.2.16. Nuclear Magnetic Resonance (NMR) Spectroscopy and Mass Spectrometry (MS) for BLs

Briefly, 1H-NMR (500 MHz) and 13C-NMR (500 MHz) spectra were recorded on a Bruker AC 500 spectrometer (Bruker, Karlsruhe, Germany) in an appropriate solvent with tetramethylsilane (TMS) as an internal reference. High resolution mass spectrometry (HRMS) data were recorded on UPLC/Q-TOF, equipped with an ESI source (Agilent Technologies, Santa Clara, CA, USA).
(BL-1) White solid; yield, 51.2%; 1H NMR (500 MHz, DMSO-d6) δ 10.59 (s, 1H, Ar-OH), 9.81 (s, 1H, Ar-C=C-OH), 7.47 (d, J = 8.8 Hz, 2H, Ar-H), 7.13 (dd, J = 8.3, 2.2 Hz, 1H, Ar-H), 7.02 (d, J = 2.2 Hz, 1H, Ar-H), 6.73 (t, J = 8.2 Hz, 3H, Ar-H), 6.38 (d, J = 9.8 Hz, 1H, Ar-CH=CH), 6.35 (s, 1H, COO-CH-Ar), 5.73 (d, J = 9.9 Hz, 1H, CH=CH-C), 1.34 (d, J = 2.7 Hz, 6H, CH3-C-CH3). 13C NMR (126 MHz, DMSO-d6) δ 169.79, 158.16, 153.49, 136.96, 131.88, 129.59, 129.52, 129.48, 129.13, 126.03, 122.05, 121.80, 121.58, 116.58, 115.81, 79.87, 76.92, 28.29, 28.27. HRMS (ESI+) calculated for C21H18O5 [M + H]+: 351.1227, found: 351.1227.
(BL-2) White solid; yield, 49.4%; 1H NMR (500 MHz, DMSO-d6) δ 10.56 (s, 1H, Ar-C=C-OH), 9.79 (s, 1H, Ar-OH), 7.45 (d, J = 8.8 Hz, 2H, Ar-H), 7.26 (d, J = 8.7 Hz, 2H, Ar-H), 6.91 (d, J = 8.7 Hz, 2H, Ar-H), 6.72 (d, J = 8.8 Hz, 2H, Ar-H), 6.40 (s, 1H, COO-CH-Ar), 5.40 (m, 1H, CH=C(CH3)2), 4.49 (d, J = 6.7 Hz, 2H, Ar-OCH2), 1.73 (s, 3H, CH3-C-CH3), 1.68 (s, 3H, CH3-C-CH3). 13C NMR (126 MHz, DMSO-d6) δ 169.83, 159.45, 158.13, 137.74, 136.90, 129.64, 129.61, 129.40, 129.09, 122.06, 120.18, 115.77, 115.30, 79.80, 64.75, 25.87, 18.45. HRMS (ESI+) calculated for C21H20O5 [M + H]+: 353.1384, found: 353.1378.
(BL-3) White solid; yield, 52.2%; 1H NMR (500 MHz, DMSO-d6) δ 10.56 (s, 1H, Ar-OH), 9.80 (s, 1H, Ar-C=C-OH), 7.49 − 7.41 (m, 5H, Ar-H), 7.39 (t, J = 7.5 Hz, 2H, Ar-H), 7.33 (d, J = 7.3 Hz, 1H, Ar-H), 7.15 (dd, J = 8.4, 2.2 Hz, 1H, Ar-H), 7.11 (d, J = 2.2 Hz, 1H, Ar-H), 7.01 (d, J = 8.5 Hz, 1H, Ar-H), 6.73 (d, J = 8.9 Hz, 2H, Ar-H), 6.38 (s, 1H, COO-CH-Ar), 5.19 (m, 1H, CH=C(CH3)2), 5.08 (s, 2H, Ar-CH2), 3.23 (d, J = 7.2 Hz, 2H, Ar-CH2-CH), 1.58 (d, J = 62.8 Hz, 6H, CH3-C-CH3). 13C NMR (126 MHz, DMSO-d6) δ 169.85, 158.12, 137.53, 136.87, 132.42, 130.28, 129.61, 129.49, 129.30, 129.11, 128.87, 128.24, 127.91, 127.29, 122.56, 122.13, 115.75, 112.43, 79.94, 69.75, 28.90, 25.94, 18.01. HRMS (ESI+) calculated for C28H26O5 [M + H]+: 443.1853, found: 443.1859.
(BL-4) Yellow solid; yield, 57.9%; 1H NMR (500 MHz, DMSO-d6) δ 11.27 (s, 1H, Ar-OH), 9.91 (s, 1H, Ar-C=C-OH), 7.55 (d, J = 8.9 Hz, 2H, Ar-H), 7.45 (d, J = 7.2 Hz, 2H, Ar-H), 7.40 (t, J = 7.4 Hz, 2H, Ar-H), 7.34 (s, 1H, Ar-H), 7.26 (d, J = 8.8 Hz, 2H, Ar-H), 7.04 (d, J = 8.9 Hz, 2H, Ar-H), 6.75 (d, J = 8.9 Hz, 2H, Ar-H), 5.12 (s, 2H, Ar-CH2), 3.74 (s, 3H, COO-CH3). 13C NMR (126 MHz, DMSO-d6) δ 169.37, 168.25, 159.49, 158.33, 138.89, 137.21, 130.53, 130.36, 128.91, 128.39, 128.23, 121.26, 115.63, 115.18, 87.05, 69.82, 54.01. HRMS (ESI+) calculated for C25H20O7 [M + H]+: 433.1282, found: 433.1285.
(BL-5) White solid; yield, 48.5%; 1H NMR (500 MHz, Acetone-d6) δ 8.87 (s, 1H, Ar-OH), 8.78 (s, 1H, Ar-C=C-OH), 7.71 (d, J = 8.7 Hz, 2H, Ar-H), 7.47 (d, J = 7.4 Hz, 2H, Ar-H), 7.39 (t, J = 7.4 Hz, 2H, Ar-H), 7.33 (t, J = 7.3 Hz, 1H, Ar-H), 7.01 (dd, J = 8.8, 2.5 Hz, 4H, Ar-H), 6.88 (d, J = 8.6 Hz, 2H, Ar-H), 5.66 (dd, J = 6.2, 3.4 Hz, 1H, COO-CH-CH2), 5.07 (s, 2H, Ar-CH2), 3.33 (dd, J = 14.7, 3.3 Hz, 1H, CH-CH2-Ar), 2.91 (dd, J = 14.7, 6.2 Hz, 1H, CH-CH2-Ar). 13C NMR (126 MHz, Acetone-d6) δ 157.94, 157.80, 137.57, 136.56, 130.79, 129.26, 129.09, 128.36, 127.74, 127.69, 127.56, 115.71, 114.25, 78.37, 69.48, 38.55. HRMS (ESI+) calculated for C24H20O5 [M + H]+: 389.1384, found: 389.1386.
(BL-6) White solid; yield, 43.7%; 1H NMR (500 MHz, Acetone-d6) δ 8.86 (s, 1H, Ar-OH), 8.74 (s, 1H, Ar-C=C-OH), 7.70 (d, J = 8.8 Hz, 2H, Ar-H), 7.49 (d, J = 7.4 Hz, 2H, Ar-H), 7.40 (t, J = 7.5 Hz, 2H, Ar-H), 7.33 (d, J = 7.3 Hz, 1H, Ar-H), 7.05–6.98 (m, 2H, Ar-H), 6.87 (s, 2H, Ar-H), 6.81 (s, 1H, Ar-H), 5.66 (dd, J = 5.7, 3.5 Hz, 1H, COO-CH-CH2), 5.22 (m, 1H, CH=C(CH3)2), 5.08 (s, 2H, Ar-CH2), 3.34−3.24 (m, 3H, CH-CH2-Ar, Ar-CH2-CH), 2.92 (dd, J = 14.7, 5.7 Hz, 1H, CH-CH2-Ar), 1.69 (s, 3H, CH3-C-CH3), 1.62 (s, 3H, CH3-C-CH3). 13C NMR (126 MHz, Acetone-d6) δ 168.85, 157.91, 155.31, 137.79, 130.95, 129.42, 129.25, 129.04, 128.34, 128.25, 127.61, 127.40, 127.27, 122.78, 122.51, 115.67, 111.21, 78.27, 69.60, 38.47, 25.06, 17.01. HRMS (ESI+) calculated for C29H28O5 [M + H]+: 457.2010, found: 457.2015.
(BL-3-1) White solid; 1H NMR (500 MHz, Acetone-d6) δ 8.82 (s, 2H, Ar-C=C-OH, Ar-OH), 7.58 (d, J = 8.8 Hz, 2H, Ar-H), 7.49 (d, J = 7.4 Hz, 2H, Ar-H), 7.40 (t, J = 7.5 Hz, 2H, Ar-H), 7.34 (d, J = 7.3 Hz, 1H, Ar-H), 7.26−7.20 (m, 2H, Ar-H), 7.02 (d, J = 8.1 Hz, 1H, Ar-H), 6.82 (d, J = 8.8 Hz, 2H, Ar-H), 6.30 (s, 1H, COO-CH-Ar), 5.26 (m, 1H, CH=C(CH3)2), 5.13 (s, 2H, Ar-CH2), 3.33 (d, J = 7.3 Hz, 2H, Ar-CH2-CH), 1.68 (s, 3H, CH3-C-CH3), 1.58 (s, 3H, CH3-C-CH3). 13C NMR (126 MHz, Acetone-d6) δ 169.14, 157.79, 157.17, 137.43, 132.12, 130.53, 129.51, 129.29, 128.95, 128.43, 128.37, 127.72, 127.44, 126.96, 122.44, 122.26, 115.28, 111.83, 80.27, 69.71, 24.95, 16.93. HRMS (ESI+) calculated for C28H26O5 [M + Na]+: 465.1676, found: 465.1666.
(BL-3-2) White solid; 1H NMR (500 MHz, Acetone-d6) δ 8.91 (s, 2H, Ar-C=C-OH, Ar-OH), 7.58 (d, J = 8.8 Hz, 2H, Ar-H), 7.49 (d, J = 7.3 Hz, 2H, Ar-H), 7.40 (t, J = 7.5 Hz, 2H, Ar-H), 7.33 (t, J = 7.3 Hz, 1H, Ar-H), 7.23 (d, J = 8.4 Hz, 2H, Ar-H), 7.02 (d, J = 8.1 Hz, 1H, Ar-H), 6.82 (d, J = 8.8 Hz, 2H, Ar-H), 6.30 (s, 1H, COO-CH-Ar), 5.26 (m, 1H, CH=C(CH3)2), 5.13 (s, 2H, Ar-CH2), 3.33 (d, J = 7.3 Hz, 2H, Ar-CH2-CH), 1.68 (s, 3H, CH3-C-CH3), 1.58 (s, 3H, CH3-C-CH3). 13C NMR (126 MHz, Acetone-d6) δ 169.13, 157.79, 157.17, 137.43, 136.72, 132.12, 130.53, 129.52, 129.29, 128.94, 128.38, 127.72, 127.44, 126.97, 122.44, 122.26, 115.29, 111.83, 80.28, 69.71, 24.95, 16.93. HRMS (ESI+) calculated for C28H26O5 [M + Na]+: 465.1676, found: 465.1684.
(BL-5-1) White solid; 1H NMR (500 MHz, DMSO-d6) δ 10.01 (s, 2H, Ar-OH, Ar-C=C-OH), 7.60 (d, J = 8.5 Hz, 2H, Ar-H), 7.44 (d, J = 7.5 Hz, 2H, Ar-H), 7.39 (t, J = 7.4 Hz, 2H, Ar-H), 7.33 (t, J = 7.2 Hz, 1H, Ar-H), 6.97–6.85 (m, 6H, Ar-H), 5.68 (dd, J = 6.1, 3.4 Hz, 1H, COO-CH-CH2), 5.04 (s, 2H, Ar-CH2), 3.21 (dd, J = 14.6, 3.0 Hz, 1H, CH-CH2-Ar), 2.76 (dd, J = 14.7, 6.3 Hz, 1H, CH-CH2-Ar). 13C NMR (126 MHz, DMSO-d6) δ 158.24, 157.59, 137.62, 131.07, 129.39, 128.84, 128.22, 128.15, 128.11, 122.19, 116.11, 114.69, 78.32, 69.63, 38.78. HRMS (ESI+) calculated for C24H20O5 [M + H]+: 389.1384, found: 389.1382.
(BL-5-2) White solid; 1H NMR (500 MHz, DMSO-d6) δ 9.96 (d, 2H, Ar-OH, Ar-C=C-OH), 7.60 (d, J = 8.7 Hz, 2H, Ar-H), 7.44 (d, J = 7.1 Hz, 2H, Ar-H), 7.39 (t, J = 7.5 Hz, 2H, Ar-H), 7.33 (d, J = 7.2 Hz, 1H, Ar-H), 6.98–6.84 (m, 6H, Ar-H), 5.68 (dd, J = 6.3, 3.4 Hz, 1H, COO-CH-CH2), 5.04 (s, 2H, Ar-CH2), 3.21 (dd, J = 14.7, 3.4 Hz, 1H, CH-CH2-Ar), 2.76 (dd, J = 14.7, 6.4 Hz, 1H, CH-CH2-Ar). 13C NMR (126 MHz, DMSO-d6) δ 158.23, 157.59, 137.62, 136.85, 131.07, 129.39, 128.84, 128.22, 128.16, 128.11, 122.18, 116.11, 114.69, 78.32, 69.63, 38.77. HRMS (ESI+) calculated for C24H20O5 [M + H]+: 389.1384, found: 389.1385.

3.3. Biological Evaluation

3.3.1. PTP1B Inhibitory Assay

The tested compounds at designated concentrations were solubilized in DMSO, and 2 μL samples was added to 96-well clear polystyrene plate. The DMSO (2 μL) was set as the full enzyme activity, and Na3VO4 (2 μL) was set as the positive control. Then, 78 μL of an assay buffer (25 mM Hepes, 150 mM sodium chloride (NaCl), 0.1% bovine serum albumin (BSA), 3 mM dithiothreitol, 1 mM ethylenediaminetetraacetic acid) and 10 μL of the PTP1B (10 μg/mL) was added and incubated for 10 min at 37 °C. The screening was initiated by adding 10 μL p-nitrophenyl phosphate (pNPP), and the catalysis of pNPP (1 mM) was continuously monitored on SpectraMax 340 microplate reader (Molecular Devices, Sunnyvale, CA, USA) at 405 nm for 20 min at 37 °C. The slope of the linear portion of the kinetic curve generated from each well was used to determine the activity of PTP1B. The inhibition effect of the compound was represented by the percentage of the slope of the linear portion of its kinetic curve relative to that of the negative control (DMSO). The IC50 was calculated with Prism 8 software (Graphpad, San Diego, CA, USA) from the non-linear curve fitting of the percentage of inhibition (%inhibition) versus the inhibitor concentration [I] by using the following equation: %Inhibition = 100/(1 + [IC50/[I]] k), where k is the Hill coefficient.

3.3.2. Establishment of HepG2 Cell Insulin Resistance Model and Evaluation of BLs

HepG2 cells (Cell Bank of Chinese Academy of Sciences, Shanghai, China) were seeded in 96-well plates in normal Dulbecco’s Modified Eagle’ Medium (DMEM, 5.6 mM glucose) supplemented with 10% fetal bovine serum (FBS). The density of the cells in each plate was 1 × 104 cells/mL. The original medium was removed when the cells became adherent. For the control group, the medium was replaced with high glucose DMEM (30 mM glucose). The model of insulin resistance was established by stimulation with high glucose DMEM (30 mM glucose) with 10−7 mol/L insulin for 48 h. Then, the cells were treated with drug-free or drug-containing DMEM (5.6 mM glucose) containing 0.2% BSA and milk 1 × 10−9 mol/L insulin for 24 h. Glucose consumption was detected with the glucose oxidase method using a glucose assay kit (Cat#BC2500, Solarbio, Beijing, China).

3.3.3. Cell Proliferation Assay

The cytotoxic effect of the synthesized butenolides on RIN-m5f (CRL-11605, American Type Culture Collection, Manassas, VA, USA) and HepG2 cells was determined with a Cell Counting Kit 8 (CCK-8) kit (Dojindo, Tokyo, Japan) [51,52]. Cells were seeded into 96-well plates in DMEM with 10% FBS in a volume of 100 µL per well and cultured overnight at 37 °C. The density of the cells in each plate was 1 × 104 cells/mL. According to the manufacturer’s protocol, after treatment with DMSO or varying concentrations of BLs for 48 h, 10 µL of CCK-8 solution was added to each well and cells were incubated for 2 h at 37 °C. Measure the absorbance at 450 nm of each well on a SpectraMax 340 microplate reader.

3.3.4. Molecular Docking Simulations

Molecular docking was performed using Maestro software (Version 10.2.010, Schrödinger, LLC, New York, NY, USA), and all calculations utilized the standard default settings. The published PTP1B crystal structure (PDB ID: 1NNY) was used as a basis set for this task [53]. The binding region was defined as 15 Å around the ligand 515 in the crystal structure. The types of interaction of the complex and ligand were analyzed by PyMOL Molecular Graphics System (Version 2.32, DeLano Scientific LLC, Palo Alto, CA, USA) after the molecular docking.

4. Conclusions

In this study, six racemic butenolides were synthesized by the modification on the C-4 position of butyrolactone I, two of which displayed significant hypoglycemic activities, and the underlying mechanism may be the inhibition of the PTP1B. Additionally, our data suggested that the chirality might influence the interactions between the compounds and PTP1B. Our study provides novel approaches to synthesize butyrolactone derivatives for the treatment of T2DM.

Author Contributions

Conceptualization, B.H., J.H. and M.X.; methodology, B.H. and M.X.; software, J.H.; validation, J.H., C.F., C.T. and Q.L.; formal analysis, B.H.; investigation, J.H. and K.B.; resources, C.F., C.T. and Q.L.; data curation, J.H.; writing-original draft preparation, B.H.; writing-review and editing, J.H. and S.N.; visualization, J.H.; supervision, B.H. and M.X.; project administration, B.H.; funding acquisition, B.H. All authors have read and agreed to the published version of the manuscript.

Funding

This research was funded by Scientific Research Foundation of the Third Institute of Oceanography, Ministry of Natural Resources [grant number 2018013], the Xiamen Marine Economic Innovation and Development Demonstration Project (grant number 16CZP012SF04). and the Beihai Marine Economic Innovation and Development Demonstration Project (grant number Bhsfs010).

Conflicts of Interest

The authors declare no conflict of interest.

Abbreviations

BSAbovine serum albumin
CCK-8Cell Counting Kit 8
CDcircular dichroism
CDKcyclin-dependent kinase
DBU1,8-diazabicyclo[5.4.0]undec-7-ene
DDQ2,3-dichloro-5,6-dicyano-1,4-benzoquinone
DMEMDulbecco’s Modified Eagle’ Medium
DMFN, N-dimethylformamide
DMSOdimethyl sulfoxide
EAethyl acetate
ECDelectronic circular dichroism
FBSfetal bovine serum
HRMShigh resolution mass spectrometry
IC50 50%percentage inhibition concentration
IRinsulin resistant
MSmass spectrometry
NMRnuclear magnetic resonance
PEpetroleum ether
pNPPp-nitrophenyl phosphate
PTP1Bprotein tyrosine phosphatase 1B
Rosrosiglitazone
T2DMtype 2 diabetes mellitus
TEMPO2,2,6,6-tetramethylpiperidine-1-oxyl
THPtetrahydropyran
TLCthin layer chromatography
TMCStrimethyl chlorosilane
TMStetramethylsilane

References

  1. Kumar, V.; Fausto, N.; Abbas, A.K.; Cotran, R.S.; Robbins, S.L. Robbins and Cotran Pathologic Basis of Disease, 7th ed.; Elsevier Saunders: Philadelphia, PA, USA, 2005; pp. 1194–1195. [Google Scholar]
  2. Faselis, C.; Katsimardou, A.; Imprialos, K.; Deligkaris, P.; Kallistratos, M.; Dimitriadis, K. Microvascular complications of type 2 diabetes mellitus. Curr. Vasc. Pharmacol. 2020, 18, 117–124. [Google Scholar] [CrossRef] [PubMed]
  3. Pirola, L. Epigenetics of Diabetic Microvascular Disease. Microvasc. Dis. Diabetes 2020, 45–57. [Google Scholar] [CrossRef]
  4. Tancredi, M.; Rosengren, A.; Svensson, A.-M.; Kosiborod, M.; Pivodic, A.; Gudbjörnsdottir, S.; Wedel, H.; Clements, M.; Dahlqvist, S.; Lind, M. Excess mortality among persons with type 2 diabetes. N. Engl. J. Med. 2015, 373, 1720–1732. [Google Scholar] [CrossRef] [PubMed] [Green Version]
  5. Wright, A.K.; Kontopantelis, E.; Emsley, R.; Buchan, I.; Sattar, N.; Rutter, M.K.; Ashcroft, D.M. Life expectancy and cause-specific mortality in type 2 diabetes: A population-based cohort study quantifying relationships in ethnic subgroups. Diabetes Care 2017, 40, 338–345. [Google Scholar] [CrossRef] [Green Version]
  6. Magliano, D.J.; Sacre, J.W.; Harding, J.L.; Gregg, E.W.; Zimmet, P.Z.; Shaw, J.E. Young-onset type 2 diabetes mellitus—Implications for morbidity and mortality. Nat. Rev. Endocrinol. 2020, 16, 321–331. [Google Scholar] [CrossRef]
  7. Figuerola, B.; Angulo-Preckler, C.; Nunez-Pons, L.; Moles, J.; Sala-Comorera, L.; Garcia-Aljaro, C.; Blanch, A.R.; Avila, C. Experimental evidence of chemical defence mechanisms in Antarctic bryozoans. Mar. Environ. Res. 2017, 129, 68–75. [Google Scholar] [CrossRef] [PubMed]
  8. La Peyre, J.F.; Xue, Q.-G.; Itoh, N.; Li, Y.; Cooper, R.K. Serine protease inhibitor cvSI-1 potential role in the eastern oyster host defense against the protozoan parasite Perkinsus marinus. Dev. Comp. Immunol. 2010, 34, 84–92. [Google Scholar] [CrossRef]
  9. Li, Q.; Wang, X.; Korzhev, M.; Schroder, H.C.; Link, T.; Tahir, M.N.; Diehl-Seifert, B.; Muller, W.E. Potential biological role of laccase from the sponge Suberites domuncula as an antibacterial defense component. Biochim. Biophys. Acta 2015, 1850, 118–128. [Google Scholar] [CrossRef]
  10. Ono, K.; Suzuki, T.A.; Toyoshima, Y.; Suzuki, T.; Tsutsui, S.; Odaka, T.; Miyadai, T.; Nakamura, O. SJL-1, a C-type lectin, acts as a surface defense molecule in Japanese sea cucumber, Apostichopus japonicus. Mol. Immunol. 2018, 97, 63–70. [Google Scholar] [CrossRef]
  11. Xie, J.; Obiefuna, V.; Hodgkinson, J.W.; McAllister, M.; Belosevic, M. Teleost antimicrobial peptide hepcidin contributes to host defense of goldfish (Carassius auratus L.) against Trypanosoma carassii. Dev. Comp. Immunol. 2019, 94, 11–15. [Google Scholar] [CrossRef]
  12. An, Y.; Zhu, H.; Deng, S.; Huang, S.; Zhang, M.; Li, D.; Wang, C.; Wu, Y.; Ma, X.; Zhang, Y. α-Furanones, secondary metabolites from the fungus Cephalotrichum microsporum and their antibacterial activities. Phytochem. Lett. 2019, 30, 58–61. [Google Scholar] [CrossRef]
  13. Byczek-Wyrostek, A.; Kitel, R.; Rumak, K.; Skonieczna, M.; Kasprzycka, A.; Walczak, K. Simple 2(5H)-furanone derivatives with selective cytotoxicity towards non-small cell lung cancer cell line A549-Synthesis, structure-activity relationship and biological evaluation. Eur. J. Med. Chem. 2018, 150, 687–697. [Google Scholar] [CrossRef]
  14. Chang, Y.; Wang, P.C.; Ma, H.M.; Chen, S.Y.; Fu, Y.H.; Liu, Y.Y.; Wang, X.; Yu, G.C.; Huang, T.; Hibbs, D.E.; et al. Design, synthesis and evaluation of halogenated furanone derivatives as quorum sensing inhibitors in Pseudomonas aeruginosa. Eur. J. Pharm. Sci. Off. J. Eur. Fed. Pharm. Sci. 2019, 140, 105058. [Google Scholar] [CrossRef] [PubMed]
  15. Lagoutte, R.; Pastor, M.; Berthet, M.; Winssinger, N. Rapid and scalable synthesis of chiral bromolactones as precursors to α-exo-methylene-γ-butyrolactone-containing sesquiterpene lactones. Tetrahedron 2018, 74, 6012–6021. [Google Scholar] [CrossRef]
  16. Wu, Y.C.; Luo, S.H.; Mei, W.J.; Cao, L.; Wu, H.Q.; Wang, Z.Y. Synthesis and biological evaluation of 4-biphenylamino-5-halo-2(5H)-furanones as potential anticancer agents. Eur. J. Med. Chem. 2017, 139, 84–94. [Google Scholar] [CrossRef] [PubMed]
  17. Norrie, P.A.; Chia, E.W.; Berridge, M.V.; Maas, E.W.; Page, M.J.; Webb, V.L.; Harper, J.L.; Copp, B.R. E/Z-rubrolide O, an anti-inflammatory halogenated furanone from the New Zealand ascidian Synoicum n. sp. J. Nat. Prod. 2007, 70, 111–113. [Google Scholar]
  18. Liao, G.; Wu, P.; Xue, J.; Liu, L.; Li, H.; Wei, X. Asperimides A-D, anti-inflammatory aromatic butenolides from a tropical endophytic fungus Aspergillus terreus. Fitoterapia 2018, 131, 50–54. [Google Scholar] [CrossRef]
  19. Felder, S.; Kehraus, S.; Neu, E.; Bierbaum, G.; Schaberle, T.F.; Konig, G.M. Salimyxins and enhygrolides: Antibiotic, sponge-related metabolites from the obligate marine myxobacterium Enhygromyxa salina. Chembiochem Eur. J. Chem. Biol. 2013, 14, 1363–1371. [Google Scholar] [CrossRef]
  20. Gao, H.; Guo, W.; Wang, Q.; Zhang, L.; Zhu, M.; Zhu, T.; Gu, Q.; Wang, W.; Li, D. Aspulvinones from a mangrove rhizosphere soil-derived fungus Aspergillus terreus Gwq-48 with anti-influenza A viral (H1N1) activity. Bioorg. Med. Chem. Lett. 2013, 23, 1776–1778. [Google Scholar] [CrossRef]
  21. Singh, P.; Mittal, A.; Bhardwaj, A.; Kaur, S.; Kumar, S. 1-Toluene-sulfonyl-3-[(3′-hydroxy-5′-substituted)-gamma-butyrolactone]-indoles: Synthesis, COX-2 inhibition and anti-cancer activities. Bioorg. Med. Chem. Lett. 2008, 18, 85–89. [Google Scholar] [CrossRef]
  22. Le Floch, C.; Le Gall, E.; Sengmany, S.; Renevret, P.; Leonel, E.; Martens, T.; Cresteil, T. Synthesis of 2,3-di- and 2,2,3-trisubstituted-3-methoxycarbonyl-gamma-butyrolactones as potent antitumor agents. Eur. J. Med. Chem. 2015, 89, 654–670. [Google Scholar] [CrossRef] [PubMed]
  23. Dai, G.F.; Xu, H.W.; Wang, J.F.; Liu, F.W.; Liu, H.M. Studies on the novel alpha-glucosidase inhibitory activity and structure-activity relationships for andrographolide analogues. Bioorg. Med. Chem. Lett. 2006, 16, 2710–2713. [Google Scholar] [CrossRef] [PubMed]
  24. Haroon, M.H.; Premaratne, S.R.; Choudhry, M.I.; Dharmaratne, H.R. A new beta-glucuronidase inhibiting butyrolactone from the marine endophytic fungus Aspergillus terreus. Nat. Prod. Res. 2013, 27, 1060–1066. [Google Scholar] [CrossRef]
  25. Eleftheriou, P.; Geronikaki, A.; Petrou, A. PTP1b Inhibition, A Promising Approach for the Treatment of Diabetes Type II. Curr. Top Med. Chem. 2019, 19, 246–263. [Google Scholar] [CrossRef]
  26. Nong, X.-H.; Wang, Y.-F.; Zhang, X.-Y.; Zhou, M.-P.; Xu, X.-Y.; Qi, S.-H. Territrem and butyrolactone derivatives from a marine-derived fungus Aspergillus terreus. Mar. Drugs 2014, 12, 6113–6124. [Google Scholar] [CrossRef] [PubMed]
  27. Zhang, Y.Y.; Zhang, Y.; Yao, Y.-B.; Lei, X.-L.; Qian, Z.-J. Butyrolactone-I from coral-derived fungus Aspergillus terreus attenuates neuro-inflammatory response via suppression of NF-κB pathway in BV-2 cells. Mar. Drugs 2018, 16, 202. [Google Scholar] [CrossRef] [Green Version]
  28. Xiao-Wei, L.; Yun, L.; Yong-Jun, L.; Xue-Feng, Z.; Yong-Hong, L. Peptides and polyketides isolated from the marine sponge-derived fungus Aspergillus terreus SCSIO 41008. Chin. J. Nat. Med. 2019, 17, 149–154. [Google Scholar]
  29. Kitagawa, M.; Okabe, T.; Ogino, H.; Matsumoto, H.; Suzuki-Takahashi, I.; Kokubo, T.; Higashi, H.; Saitoh, S.; Taya, Y.; Yasuda, H. Butyrolactone I, a selective inhibitor of cdk2 and cdc2 kinase. Oncogene 1993, 8, 2425. [Google Scholar]
  30. Hosoi, T.; Uchiyama, M.; Okumura, E.; Saito, T.; Ishiguro, K.; Uchida, T.; Okuyama, A.; Kishimoto, T.; Hisanaga, S.-I. Evidence for cdk5 as a major activity phosphorylating tau protein in porcine brain extract. J. Biochem. 1995, 117, 741–749. [Google Scholar] [CrossRef]
  31. Dewi, R.T.; Tachibana, S.; Darmawan, A. Antidiabetic and antioxidative activities of butyrolactone I from Aspergillus terreus MC751. World Acad. Sci. Eng. Technol. 2012, 70, 882–887. [Google Scholar]
  32. Dewi, R.T.; Tachibana, S.; Darmawan, A. Effect on α-glucosidase inhibition and antioxidant activities of butyrolactone derivatives from Aspergillus terreus MC751. Med. Chem. Res. 2014, 23, 454–460. [Google Scholar] [CrossRef]
  33. Wu, W.; Liu, L.; Zhu, H.; Sun, Y.; Wu, Y.; Liao, H.; Gui, Y.; Li, L.; Liu, L.; Sun, F. Butyrolactone-I, an efficient α-glucosidase inhibitor, improves type 2 diabetes with potent TNF-α–lowering properties through modulating gut microbiota in db/db mice. FASEB J. 2019, 33, 12616–12629. [Google Scholar] [CrossRef] [PubMed] [Green Version]
  34. Ahn, S.; Jang, D.M.; Park, S.C.; An, S.; Shin, J.; Han, B.W.; Noh, M. Cyclin-Dependent Kinase 5 Inhibitor Butyrolactone I Elicits a Partial Agonist Activity of Peroxisome Proliferator-Activated Receptor γ. Biomolecules 2020, 10, 275. [Google Scholar] [CrossRef] [PubMed] [Green Version]
  35. Braña, M.F.; García, M.L.; López, B.; de Pascual-Teresa, B.; Ramos, A.; Pozuelo, J.M.; Domínguez, M.T. Synthesis and biological evaluation of analogues of butyrolactone I and molecular model of its interaction with CDK2. Org. Biomol. Chem. 2004, 2, 1864–1871. [Google Scholar] [CrossRef] [PubMed]
  36. El-Tombary, A.A.; Abdel-Ghany, Y.S.; Belal, A.S.; El-Dine, S.A.S.; Soliman, F.S. Synthesis of some substituted furan-2 (5H)-ones and derived quinoxalinones as potential anti-microbial and anti-cancer agents. Med. Chem. Res. 2011, 20, 865–876. [Google Scholar] [CrossRef]
  37. Cazar, M.; Schmeda-Hirschmann, G.; Astudillo, L. Antimicrobial butyrolactone I derivatives from the Ecuadorian soil fungus Aspergillus terreus Thorn. var terreus. World J. Microbiol. Biotechnol. 2005, 21, 1067–1075. [Google Scholar] [CrossRef]
  38. Fatope, M.O.; Okogun, J.I. A convenient solvent-specific synthesis of 4-[4-acetoxy-3-(3-methylbut-2-enyl)phenyl]butyric acid. J. Chem. Soc. Perkin Trans. 1982, 40, 1601–1603. [Google Scholar] [CrossRef]
  39. Kishali, N.; Polat, M.F.; Altundas, R.; Kara, Y. A Novel One-Pot Conversion of Allyl Alcohols into Primary Allyl Halides Mediated by Acetyl Halide. Helvetica Chimica Acta 2008, 91, 67–72. [Google Scholar] [CrossRef]
  40. Yang, Y.-L.; Zhou, H.; Du, G.; Feng, K.-N.; Feng, T.; Fu, X.-L.; Liu, J.-K.; Zeng, Y. A Monooxygenase fromBoreostereum vibransCatalyzes Oxidative Decarboxylation in a Divergent Vibralactone Biosynthesis Pathway. Angew. Chem. Int. Ed. 2016, 55, 5463–5466. [Google Scholar] [CrossRef]
  41. Lee, J.; Lee, J.H.; Kim, S.Y.; Perry, N.A.; Lewin, N.E.; Ayres, J.A.; Blumberg, P.M. 2-Benzyl and 2-phenyl-3-hydroxypropyl pivalates as protein kinase C ligands. Bioorg. Med. Chem. 2006, 14, 2022–2031. [Google Scholar] [CrossRef]
  42. Miyashita, M.; Yoshikoshi, A.; Grieco, P.A. Pyridinium p-toluenesulfonate. A mild and efficient catalyst for the tetrahydropyranylation of alcohols. J. Org. Chem. 1997, 42, 3772–3774. [Google Scholar] [CrossRef]
  43. Cativiela, C.; Fraile, J.M.; García, J.I.; Lázaro, B.; Mayoral, J.A.; Pallarés, A. The replacement of mineral acids by sulfonic resins in the synthesis of rac-5-(4-hydroxyphenyl)hydantoin from p-hydroxymandelic acid and urea. Appl. Catal. Gen. 2004, 274, 9–14. [Google Scholar] [CrossRef]
  44. Wei, G.; Li, J.; Fan, N.; Wu, W.; Xia, C. A Simple and Effective Method for Chemoselective Esterification of Phenolic Acids. Cheminform 2005, 36, 145–152. [Google Scholar]
  45. Hackbusch, S.; Franz, A.H. Oxidative esterification of primary alcohols with TEMPO/CaCl 2/Oxone under hydrous conditions. Tetrahedron Lett. 2016, 57, 2873–2876. [Google Scholar] [CrossRef]
  46. Tidwell, T.T. Oxidation of Alcohols by Activated Dimethyl Sulfoxide and Related Reactions: An Update. Synthesis 1990, 1990, 857–870. [Google Scholar] [CrossRef]
  47. Namiki, T.; Baba, Y.; Suzuki, Y.; Nishikawa, M.; Sawada, K.; Itoh, Y.; Oku, T.; Kitaura, Y.; Hashimoto, M. Synthesis and aldose reductase-inhibitory activities of structural analogues of WF-3681, a novel aldose reductase inhibitor. Chem. Pharm. Bull. 1988, 36, 1404. [Google Scholar] [CrossRef] [Green Version]
  48. Zhang, W.; Hong, D.; Zhou, Y.; Zhang, Y.; Shen, Q.; Li, J.Y.; Hu, L.H.; Li, J. Ursolic acid and its derivative inhibit protein tyrosine phosphatase 1B, enhancing insulin receptor phosphorylation and stimulating glucose uptake. Biochim. Biophys. Acta 2006, 1760, 1505–1512. [Google Scholar] [CrossRef]
  49. Gaussian 09; Revision C.01; Gaussian, Inc.: Wallingford, CT, USA, 2009.
  50. Stephens, P.J.; Harada, N. ECD cotton effect approximated by the Gaussian curve and other methods. Chirality Pharmacol. Biol. Chem. Conseq. Mol. Asymmetry 2010, 22, 229–233. [Google Scholar] [CrossRef]
  51. Ishiyama, M.; Miyazono, Y.; Sasamoto, K.; Ohkura, Y.; Ueno, K. A highly water-soluble disulfonated tetrazolium salt as a chromogenic indicator for NADH as well as cell viability. Talanta 1997, 44, 1299–1305. [Google Scholar] [CrossRef]
  52. Tominaga, H.; Ishiyama, M.; Ohseto, F.; Sasamoto, K.; Hamamoto, T.; Suzuki, K.; Watanabe, M. A water-soluble tetrazolium salt useful for colorimetric cell viability assay. Anal. Commun. 1999, 36, 47–50. [Google Scholar] [CrossRef]
  53. Szczepankiewicz, B.G.; Liu, G.; Hajduk, P.J.; Abad-Zapatero, C.; Pei, Z.; Xin, Z.; Lubben, T.H.; Trevillyan, J.M.; Stashko, M.A.; Ballaron, S.J. Discovery of a potent, selective protein tyrosine phosphatase 1B inhibitor using a linked-fragment strategy. J. Am. Chem. Soc. 2003, 125, 4087–4096. [Google Scholar] [CrossRef] [PubMed]
Marinedrugs 18 00526 g001 550
Figure 1. Structures of butyrolactone I and the synthesized compounds BL-1–BL-6.
Figure 1. Structures of butyrolactone I and the synthesized compounds BL-1–BL-6.
Marinedrugs 18 00526 g001
Marinedrugs 18 00526 sch001 550
Scheme 1. Synthesis of the active methylene intermediate S2.
Scheme 1. Synthesis of the active methylene intermediate S2.
Marinedrugs 18 00526 sch001
Marinedrugs 18 00526 sch002 550
Scheme 2. Synthesis of the first type of carbonyl compounds 1c, 1d and 1e.
Scheme 2. Synthesis of the first type of carbonyl compounds 1c, 1d and 1e.
Marinedrugs 18 00526 sch002
Marinedrugs 18 00526 sch003 550
Scheme 3. Synthesis of the second type of carbonyl compound 2d.
Scheme 3. Synthesis of the second type of carbonyl compound 2d.
Marinedrugs 18 00526 sch003
Marinedrugs 18 00526 sch004 550
Scheme 4. Synthesis of the third type of carbonyl compounds 3e and 3f.
Scheme 4. Synthesis of the third type of carbonyl compounds 3e and 3f.
Marinedrugs 18 00526 sch004
Marinedrugs 18 00526 sch005 550
Scheme 5. Synthesis of BL-1–BL-6.
Scheme 5. Synthesis of BL-1–BL-6.
Marinedrugs 18 00526 sch005
Marinedrugs 18 00526 g002 550
Figure 2. BLs influenced glucose consumed in IR HepG2 cell without inhibiting cell viability at designated concentration. (a) Glucose consumed. (b) HepG2 cell viability. #### p < 0.0001 vs. Normal, * p < 0.05 vs. IR, **** p < 0.0001 vs. IR. Mean ± SD (n = 6).
Figure 2. BLs influenced glucose consumed in IR HepG2 cell without inhibiting cell viability at designated concentration. (a) Glucose consumed. (b) HepG2 cell viability. #### p < 0.0001 vs. Normal, * p < 0.05 vs. IR, **** p < 0.0001 vs. IR. Mean ± SD (n = 6).
Marinedrugs 18 00526 g002
Marinedrugs 18 00526 g003 550
Figure 3. BL-6 inhibited RIN-m5f cell proliferation. *** p < 0.001 vs. Normal. Mean ± SD (n = 6).
Figure 3. BL-6 inhibited RIN-m5f cell proliferation. *** p < 0.001 vs. Normal. Mean ± SD (n = 6).
Marinedrugs 18 00526 g003
Marinedrugs 18 00526 g004 550
Figure 4. The influence of chirality of BL-3 and BL-5 on glucose consumed. #### p < 0.0001 vs. Normal, * p < 0.05 vs. IR, *** p < 0.001 vs. IR, **** p < 0.0001 vs. IR. Mean ± SD (n = 6).
Figure 4. The influence of chirality of BL-3 and BL-5 on glucose consumed. #### p < 0.0001 vs. Normal, * p < 0.05 vs. IR, *** p < 0.001 vs. IR, **** p < 0.0001 vs. IR. Mean ± SD (n = 6).
Marinedrugs 18 00526 g004
Marinedrugs 18 00526 g005 550
Figure 5. IC50 value determinations of (a) BL-1, (b) BL-2, (c) BL-3, (d) BL-4, (e) BL-5, (f) BL-6 and (g) Na3VO4 against PTP1B. Mean ± SD (n = 4).
Figure 5. IC50 value determinations of (a) BL-1, (b) BL-2, (c) BL-3, (d) BL-4, (e) BL-5, (f) BL-6 and (g) Na3VO4 against PTP1B. Mean ± SD (n = 4).
Marinedrugs 18 00526 g005
Marinedrugs 18 00526 g006 550
Figure 6. Experimental (Exp.) and calculated (Cal.) Circular dichroism (CD) spectra of (a) BL-3 and (b) BL-5.
Figure 6. Experimental (Exp.) and calculated (Cal.) Circular dichroism (CD) spectra of (a) BL-3 and (b) BL-5.
Marinedrugs 18 00526 g006
Marinedrugs 18 00526 g007 550
Figure 7. Interaction modes of (a) BL-3(R) and (b) BL-3(S) with PTP1B. Hydrogen bonds with residues are represented by dashed lines.
Figure 7. Interaction modes of (a) BL-3(R) and (b) BL-3(S) with PTP1B. Hydrogen bonds with residues are represented by dashed lines.
Marinedrugs 18 00526 g007
Marinedrugs 18 00526 g008 550
Figure 8. Interaction modes of (a) BL-5(R) and (b) BL-5(S) with PTP1B. Hydrogen bonds with residues are represented by dashed lines.
Figure 8. Interaction modes of (a) BL-5(R) and (b) BL-5(S) with PTP1B. Hydrogen bonds with residues are represented by dashed lines.
Marinedrugs 18 00526 g008
Publisher’s Note: MDPI stays neutral with regard to jurisdictional claims in published maps and institutional affiliations.

Share and Cite

MDPI and ACS Style

Hong, B.; He, J.; Fan, C.; Tang, C.; Le, Q.; Bai, K.; Niu, S.; Xiao, M. Synthesis and Biological Evaluation of Analogues of Butyrolactone I as PTP1B Inhibitors. Mar. Drugs 2020, 18, 526. https://doi.org/10.3390/md18110526

AMA Style

Hong B, He J, Fan C, Tang C, Le Q, Bai K, Niu S, Xiao M. Synthesis and Biological Evaluation of Analogues of Butyrolactone I as PTP1B Inhibitors. Marine Drugs. 2020; 18(11):526. https://doi.org/10.3390/md18110526

Chicago/Turabian Style

Hong, Bihong, Jianlin He, Chaochun Fan, Chao Tang, Qingqing Le, Kaikai Bai, Siwen Niu, and Meitian Xiao. 2020. "Synthesis and Biological Evaluation of Analogues of Butyrolactone I as PTP1B Inhibitors" Marine Drugs 18, no. 11: 526. https://doi.org/10.3390/md18110526

APA Style

Hong, B., He, J., Fan, C., Tang, C., Le, Q., Bai, K., Niu, S., & Xiao, M. (2020). Synthesis and Biological Evaluation of Analogues of Butyrolactone I as PTP1B Inhibitors. Marine Drugs, 18(11), 526. https://doi.org/10.3390/md18110526

Note that from the first issue of 2016, this journal uses article numbers instead of page numbers. See further details here.

Article Metrics

Back to TopTop